March 07, 2026 12:48 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Sensex, Nifty tumble as global tensions and Dow selloff rattle Indian markets | Two IAF pilots killed as Su-30MKI fighter jet crashes in Assam | 'Who is the US to permit?': Congress slams Modi govt over Trump administration’s waiver on India’s Russian oil purchase | US makes surprise move: India gets 30-day waiver to buy Russian oil amid global supply crisis | India edge England by 7 runs in thriller to reach T20 World Cup 2026 final | 'Guest of India struck in international waters': Iran furious after US submarine torpedoes IRIS Dena | Bihar's 'Susashan Babu' Nitish Kumar announces exit as CM, set for Rajya Sabha debut | ‘Baseless’: India rejects claims US used its ports to strike Iran | Defiant silence: Iran women’s team refuses anthem days after Khamenei’s death | 'You’ll find out soon': Trump hints at massive retaliation after Riyadh attack, says ‘boots on ground’ may not be needed

Lupin launches generic Aricept tablets in the US

| | Mar 31, 2016, at 09:23 pm
Mumbai/ Baltimore, Mar 31 (IBNS) Mumbai-based Lupin Limited (Lupin), a transnational pharmaceutical company producing and developing a wide range of branded and generic formulations, biotechnology products and APIs globally, announced on Thursday that its US subsidiary, Lupin Pharmaceuticals Inc. has launched its Donepezil Hydrochloride Tablets, 23 mg having received approval from the United States Food and Drug Administration (FDA) earlier to market a generic equivalent of Eisai Inc's Aricept® Tablets, 23mg.
Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. works in the area of generic medicines and branded formulations.
 
Lupin's Donepezil Hydrochloride Tablets, 23 mg are the AB rated generic equivalent of Eisai Inc's Aricept® Tablets, 23mg. It is indicated for the treatment of dementia of the Alzheimer's type.
 
Aricept® had US sales of USD 47.1 million (IMS MAT December 2015).

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm